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Abstract
Objectives Since the introduction of non-vitamin K
antagonist (VKA) oral anticoagulants (NOACs), an addi-
tional treatment option, apart from VKAs, has become
available for stroke prevention in patients with atrial fib-
rillation (AF). For various reasons, it is important to con-
sider patients’ preferences regarding type of medication,
particularly in view of the established relationship between
preferences towards treatment, associated burden of treat-
ment, and treatment adherence. This review aimed to sys-
tematically analyse the scientific literature assessing the
preferences of AF patients with regard to long-term oral
anticoagulant (OAC) treatment.
Methods We searched the MEDLINE, Scopus and
EMBASE databases (from 1980 to 2015), added records
from reference lists of publications found, and conducted a
systematic review based on all identified publications.
Outcomes of interest included any quantitative information
regarding the opinions or preferences of AF patients
towards OAC treatment, ideally specified according to
different clinical or convenience attributes describing dif-
ferent OAC treatment options.
Results Overall, 27 publications describing the results
of studies conducted in 12 different countries were
included in our review. Among these, 16 studies anal-
ysed patient preferences towards OACs in general.
These studies predominantly assessed which benefits
(mainly lower stroke risk) AF patients would require to
tolerate harms (mainly higher bleeding risk) associated
with an OAC. Most studies showed that patients were
willing to accept higher bleeding risks if a certain
threshold in stroke risk reduction could be reached.
Nevertheless, most of the publications also showed that
the preferences of AF patients towards OACs may
differ from the perspective of clinical guidelines or the
perspective of physicians. The remaining 11 studies
included in our review assessed the preferences of AF
patients towards specific OAC medication options,
namely NOACs versus VKAs. Our review showed that
AF patients prefer easy-to-administer treatments, such
as treatments that are applied once daily without any
food/drug interactions and without the need for bridg-
ing and frequent blood controls.
Conclusion Stroke risk reduction and a moderate increase
in the risk of bleeding are the most important attributes for
an AF patient when deciding whether they are for or
against OAC treatment. If different anticoagulation options
have similar clinical characteristics, convenience attributes
matter to patients. In this review, AF patients favour
attribute levels that describe NOAC treatment.
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Key Points for Decision Makers
For patients with atrial fibrillation (AF), stroke risk
reduction and a moderate increase in bleeding risk
are the most important attributes of anticoagulation
treatment. AF patients are willing to accept higher
bleeding risks for significant stroke risk reductions.
When the clinical characteristics of anticoagulation
treatments are similar, patients with AF prefer easy-
to-administer treatments (i.e. once-daily application,
no food/drug interactions, no need for bridging, and
no need for frequent blood controls).
1 Introduction
With a prevalence of 1–3 % in the general population,
atrial fibrillation (AF) is the most common cardiac disorder
[1–7], and its prevalence is expected to increase markedly
in most countries in the next few years [5–8]. AF patients
have been reported to be at high risk for heart failure and
thromboembolic events [8, 9]. In particular, the risk of
ischaemic strokes is up to fivefold higher than in the gen-
eral population [6, 8–10]. Current AF guidelines recom-
mend the assessment of thromboembolic event/stroke risk
and, if a certain risk exists in a patient, lifelong oral anti-
coagulant (OAC) treatment [7, 11]. To assess the risk of
stroke in patients with AF, the CHADS2 score [12] or the
CHA2DS2-VASc score instruments have been recom-
mended [13]. Based on these, patients with a CHADS2/
CHA2DS2-VASc score C1 are at mild or high risk of stroke
and should consequently receive OAC treatment, while
patients with a score equal to 1 may receive aspirin [7, 11].
For several decades, vitamin K antagonists (VKAs) have
been the only OAC treatment option for AF patients;
however, in 2011, the first non-VKA oral anticoagulant
(NOAC) became available for these patients as an alter-
native to VKA treatment. To date, four NOACs have been
approved for stroke prevention in non-valvular AF (dabi-
gatran, rivaroxaban, apixaban, edoxaban). Most clinical
studies have shown that NOAC treatment in AF patients
with a need for anticoagulation is at least as effective and
safe as VKA treatment [14–16]; however, former studies
also indicate that a difference in patient perception may
exist with regard to the treatment options mentioned
[17–19]. This may be of particular importance because,
inherently, every treatment should be centred on the
patient. This is especially relevant in the long-term treat-
ment of chronic diseases such as AF because patient
preferences may influence not only the long-term
adherence of patients but also the physician–patient rela-
tionship and, finally, the real-world effectiveness of a
particular type of treatment [20].
Consequently, it is important to know which anticoag-
ulation treatment characteristics AF patients prefer. In line
with this, clinical guidelines highly recommend taking into
account the views and preferences of an AF patient when
deciding on OAC therapy options [7, 11, 21, 22]. In this
way, the patient is enabled to make an informed decision,
in partnership with the healthcare professionals, about their
upcoming treatment. In turn, this will enable healthcare
professionals to understand the patient’s view, which can
be assumed to be of utmost importance, especially in the
long term [22].
Little is known about the preferences of AF patients
with regard to OAC therapy; therefore, the objective of this
analysis was to conduct a systematic literature review
summarising the results of studies dealing with the pref-
erences of AF patients towards OAC treatment.
2 Methods
The methods applied in this review are consistent with
those proposed in the Preferred Reporting Items for Sys-
temic Reviews and Meta-Analyses (PRISMA) statement
[23].
2.1 Study Selection
We searched the MEDLINE, Scopus and EMBASE data-
bases (from 1980 to 2015), added records from reference
lists of publications found, and conducted a systematic
review based on all identified publications. All in all, we
conducted a literature search on the basis of 20 queries,
which included the terms ‘preferences’, ‘atrial fibrillation’
and ‘discrete choice experiment’, amongst others.1 Inclu-
sion criteria for studies were defined as follows:
1 Search strings entered in MEDLINE were ‘discrete AND choice
AND experiment AND atrial AND fibrillation’, ‘discrete AND choice
AND experiment AND anticoagulation’, ‘treatment AND preferences
AND atrial AND fibrillation’, ‘treatment AND preferences AND
atrial AND fibrillation’, ‘discrete AND choice AND experiment AND
af’, ‘discrete AND choice AND experiment AND ac’, ‘dce AND
atrial fibrillation’, ‘dce AND anticoagulation’, ‘discrete AND choice
AND experiment AND cardiac AND arrhythmia’, ‘treatment AND
preference AND cardiac AND arrhythmia’, ‘treatment AND prefer-
ences AND cardiac AND arrhythmia’, ‘anticoagulant AND discrete
AND choice’, ‘anticoagulant AND patient AND preference’, ‘discrete
AND choice AND anticoagulation’, ‘discrete AND choice AND
anticoagulant’, ‘conjoint AND preference AND anticoagulation’,
‘trade off AND preference AND anticoagulation’, ‘preference AND
atrial fibrillation’, ‘preference AND anticoagulation’, ‘preference
AND anticoagulant’.
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• The study was published between 1980 and 2015, and
written in either German or English.
• The study quantitatively assessed the opinions or
preferences of AF patients towards OAC therapy;
qualitative studies, authors’ opinions regarding patient
opinions or preferences, as well as studies dealing with
physicians’ opinions only, were excluded.
• We excluded all studies that did not describe the
questionnaire used or the applied preference elicitation
technique in sufficient detail.
Outcomes of interest included any quantitative infor-
mation about the opinions or preferences of AF patients
towards OAC treatment. If studies provided detailed
insights, or even a trade-off assessment of different (partly
competing) attributes describing OAC treatment options,
results of these assessments were included.
2.2 Assessment of Study Eligibility and Inclusion
All titles and abstracts identified through the initial search
in the digital literature were reviewed independently by
two reviewers, and any disagreements were resolved
through discussion and/or referral to a third reviewer if
necessary. Articles were excluded when they were obvi-
ously considered irrelevant, which was decided on the basis
of their titles and abstracts. Eligibility of the remaining
articles was assessed on the basis of the inclusion criteria
listed above. Systematic reviews and meta-analyses that
met the inclusion criteria were not included in our review
but were used to identify any other potentially relevant
articles. A comparison of our results with those of identi-
fied systematic reviews or meta-analyses addressing similar
topics is presented in the Discussion section of this paper.
The methodological quality and the main characteristics
of the included studies were evaluated on the basis of the
following types of information:
• Addressed disease (AF only or additional diseases).
• Single-centre versus multicentre study.
• Selection of surveyed patients (random, consecutive or
convenience sample).
• Sample size (number of patients).
• Type of surveyed persons (AF patients, patients with
other cardiovascular diseases, general public).
• OAC experience of surveyed persons.
• Main study objective (assessment of patient preferences
towards OACs in general versus preferences towards
specific OAC medication types, i.e. mainly VKAs
versus NOACs).
• Preference elicitation technique used, with a focus on
how potential trade-offs between different treatment
attributes associated with different anticoagulation
options were dealt with. Here we differentiated between
studies using simple descriptive methods (e.g. self-
developed questionnaires investigating the importance
of specific attributes, based on Likert scales), trade-off/
threshold/standard gamble techniques or, more
recently, developed preference elicitation techniques
(e.g. analytical hierarchy method, traditional conjoint
analysis or discrete choice analysis). In addition, we
assessed whether the included studies primarily dealt
with clinical attributes associated with different anti-
coagulation options (mainly thromboembolic events
and bleeding rates), respective convenience attributes
(e.g. frequency of intake, interaction with other
drugs/food, regular blood controls), or both.
2.3 Data Extraction
Information regarding study design (including sample
definition and methodology), characteristics of study par-
ticipants (sample size, addressed disease), analysed attri-
butes or attribute levels in the study, and study results
(qualitative or quantitative data with regard to patient
opinions/preferences) were collected for each included
publication and are listed in Table 1.
2.4 Statistical Analysis and Synthesis
Our main focus was to investigate which anticoagulation
treatment would be preferred by AF patients. This was
done on a per-study basis; no meta-analysis was conducted
due to the expected diversity of studies in terms of analysed
samples and methodology used to elicit preferences.
3 Results
3.1 Study Selection and Characteristics
The electronic search identified 4577 records, including
duplicates, and 1249 records after duplicates were removed
(Fig. 1). Based on the screening of titles, a further 1184
records (94.8 %) were removed, with an additional 19
records being removed after screening of the abstract, and
19 being removed after reading the manuscript, resulting in
27 studies being included in the review. An overview of
selected study characteristics, as well as study methodol-
ogy and study results, are provided in Table 1.
All studies used patient surveys to elicit patient prefer-
ences, with six studies including additional physician sur-
veys. The number of patients included varied between 32
and 1507, and the identified studies were conducted in 12
different countries.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































30 T. Wilke et al.
Figure 2 describes the main types of included studies;
16 studies analysed patient preferences towards OAC in
general [24–39]. These studies predominantly assessed
which benefits (mainly lower stroke risk) AF patients
would require to tolerate harms (mainly higher bleeding
risk) associated with an OAC. Five of these studies were
multicentre studies that applied different techniques to
ensure a representative inclusion of patients (mean number
of patients 154) [24–28]. In these studies, the majority of
surveyed patients were current OAC users. In addition, the
majority of these five studies used a trade-off methodology
for the survey.
An additional nine studies could also be characterised as
multicentre studies but they applied a convenience sample
of patients (mean number of patients 182) [29–37]. As
previously, the majority of surveyed patients were OAC
users, and the preference elicitation technique used most
commonly was conjoint analysis. Finally, two of the
studies assessing general preferences towards OAC use
were single-centre studies (mean number of patients 538)
[38, 39]. In these studies, one used a trade-off technique
surveying OAC-naı¨ve patients, and the other used a pref-
erence questionnaire interviewing current OAC users.
The remaining 11 included studies assessed AF patient
preferences towards specific OAC medication options,
namely NOACs versus VKAs (Fig. 2) [18, 40–49]. Three
of these could be characterised as multicentre studies
ensuring a representative inclusion of patients and applying
a methodology that addressed most of the known differ-
ences between VKAs and NOACs (mean number of
patients 426) [40–42]. All of these three studies addressed
OAC users only. One study used a descriptive preference
questionnaire, while two others used conjoint analysis.
One additional multicentre study including a represen-
tative sample of 1507 AF patients (partly OAC users) used
a descriptive preference questionnaire [43]; however, this
study did not include all known differences between
NOACs and VKAs as attributes. Another study in the
Fig. 1 PRISMA
flowchart illustrating the study
selection process
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group of multicentre studies analysing preferences towards
NOACs or VKAs was based on a convenience sample of
OAC users. This study used a descriptive preference
questionnaire (290 patients) [44].
In three additional single-centre studies that included
most of the known differences between NOACs and VKAs
as attributes of the preference survey (mean number of
patients 103), one study used the trade-off technique, and two
others used conjoint or discrete choice analysis [18, 45, 46].
One study addressed currentOACusers, one study addressed
OAC-naı¨ve patients, and one study addressed members of
the general public without known OAC status.
Finally, three single-centre studies including a convenience
sample of AF patients (100 % OAC users; mean number of
patients 118) mostly used a standard gamble/trade-off tech-
nique (two studies), while one study used a preference ques-
tionnaire [47–49]. None of these studies addressed all known
differences between NOAC or VKA treatment.
3.2 Preferences of Atrial Fibrillation (AF) Patients
Towards Oral Anticoagulation Therapy
In the 16 included studies that dealt with the preferences of
AF patients towards OAC therapy in general, the main
question addressed was what degree of stroke risk
reduction AF patients would require in order to accept an
anticoagulation therapy-associated higher bleeding risk.
The five studies with the highest methodology ranking
as indicated above showed that AF patients are willing to
accept certain bleeding risks for a decrease in the proba-
bility of experiencing a stroke. However, there was sub-
stantial variability in the threshold number of bleeds
observed for the acceptance of OAC, both between the
different studies and, more so, between surveyed partici-
pants within the studies. A Spanish survey reported a
threshold of 10 additional bleeds in 2 years, while a
Canadian survey reported 17 additional bleeds in 2 years
(both for acceptance of OACs) [24, 27]. In the same sur-
vey, the minimum required stroke prevention rate for the
acceptance of OAC with its associated higher bleeding risk
was 1.8 strokes per 100 patient years. An additional
Canadian survey reported 52 % of AF patients would
accept warfarin treatment if it was associated with a 1 %
stroke risk reduction over 2 years [28]. A recent US survey
showed that AF patients valued a 1 % increased risk of a
fatal bleeding event the same as a 2 % increase in non-fatal
myocardial infarction risk, a 3 % increase in non-fatal
stroke risk, a 3 % increase in cardiovascular death risk, a
6 % increase in major bleeding risk, and a 16 % increase in
minor bleeding risk [26].
Fig. 2 Main characteristics of the included studies. VKA vitamin K antagonist, NOAC non-VKA oral anticoagulant, OAC oral anticoagulant, AF
atrial fibrillation, NA not applicable, DCE discrete choice experiment
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The results of the 11 studies with a lower methodolog-
ical quality were generally in line with the above results. In
another Canadian survey, patients required at least a 0.8 %
annual absolute stroke risk reduction and a 15 % relative
stroke risk reduction to accept antithrombotic therapy.
Patients were willing to endure 4.4 major bleeds in order to
prevent one stroke [41]. This study identified different
patient segments on the basis of general attitudes towards
anticoagulation; 12 % of patients were seen as ‘medication
averse’, meaning that they would not be willing to consider
anticoagulation therapy even if it were to be 100 %
effective. Among the other patients, 42 % were identified
as ‘risk averse’, indicating that the patients were not will-
ing to consider antithrombotic therapy if there was any
increased risk of bleeding compared with the ‘no therapy
option’, and 15 % were ‘risk tolerant’, denoting that these
patients did not appear to care about the risk of bleeding at
all. The remaining patients could not be assigned to either
of these categories [39].
Interestingly, studies comparing the general willingness
of patients to accept OAC treatment with clinical guideli-
nes concluded that significantly fewer patients (61 %)
would be willing to accept such a therapy than is recom-
mended in clinical guidelines [29]. Furthermore, several
studies found that patients and physicians evaluate stroke
and bleeding risks differently, with physicians interpreting
bleeding risks as more important and stroke risk as less
important than patients do [27, 32, 35].
3.3 Preferences of AF Patients Towards Specific
OAC Attributes
Eleven identified studies analysed patient preferences
towards OAC treatment and included, either additionally or
separately, attributes that were different from either stroke/
thromboembolic event or bleeding risk. Overall, these
attributes can be called ‘convenience attributes’ describing
NOACs and VKAs as alternative treatment options.
Among the three studies with the highest methodologi-
cal quality, one German survey analysed the preferences of
AF patients towards convenience attributes of anticoagu-
lation options [41]. Based on a discrete choice analysis of
AF patients receiving either VKAs or therapy with one
specific NOAC agent, a once-daily frequency of intake was
the most important attribute describing different treatment
options, followed by ‘no bridging necessary’, and ‘no
interactions with food/nutrition’. The authors of this par-
ticular survey concluded that German AF patients would be
willing to accept an additional distance of 29.3 km to see
the treating physician in order to receive treatment that
would incorporate once-daily intake, no necessary bridging
in case of surgeries, less food/drug interaction and an
absence of monthly blood tests, if such a treatment was
compared with VKA treatment [41]. However, in an Italian
study, only 20 % of AF patients stated they would be
willing to move from VKA to NOAC therapy. Patients not
willing to switch to an NOAC agent mentioned that the
lack of an antidote and the absence of regular laboratory
checks were the main reasons for their preference towards
VKA treatment. The majority of patients indicated that
they would prefer regular coagulation laboratory monitor-
ing during treatment with NOACs. The absence of such
monitoring would be a source of concern for patients
because they would be afraid of suffering a thrombotic or
haemorrhagic complication. Thirty-three percent of the
study population indicated that they were concerned about
forgetting to take the two daily tablets and about the
associated risk of non-adherence [40]. The third of these
studies, a recent Canadian survey, concluded that real-
world OAC prescriptions do not reflect reported patient
preferences, which suggests that other factors influence
patient–physician decision making around OAC therapy.
The authors additionally concluded that data on self-re-
ported adherence to OAC therapy and discordance in the
use of OACs from prescribed regimens raise important
concerns and warrant further investigation [41].
Here too, and as mentioned earlier, the results of the
studies with a lower methodological quality were generally
in line with the above results. With regard to their results,
no substantial differences were observed between studies
surveying different patient types (OAC users versus OAC-
naı¨ve patients) or between studies using different prefer-
ence elicitation techniques. In the majority of studies, AF
patients preferred an OAC treatment that, based on con-
venience attributes, was in line with an NOAC treatment.
All in all, of the 11 studies addressing patient preferences
towards either NOACs or VKAs, 8 concluded that AF
patients prefer NOAC therapy.
However, as illustrated by an Australian survey that
analysed AF patient preferences using a discrete choice
design including both clinical and convenience attributes
associated with either VKA or NOAC treatment, the
majority of the above studies also showed that clinical
efficacy and safety associated with an OAC alternative are
of paramount importance with respect to convenience
factors such as regular blood tests, dose frequency, or drug
or food interactions [18].
4 Discussion
4.1 Main Results and Comparison
with the Literature
Several studies analysed the attitudes of AF patients
towards OAC treatment in general, especially the view of
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AF patients towards the trade-off between a lower stroke
and higher bleeding risk. Most of the literature shows that
patients are willing to accept higher bleeding risks if a
certain threshold in reduced stroke risk can be reached.
Nevertheless, the majority of the publications also showed
that many AF patients may weigh bleeding risk and stroke
risk differently from both physicians and clinical guide-
lines. Therefore, based on the preferences of AF patients
only, fewer patients would receive anticoagulation treat-
ment than may be expected on the basis of recommenda-
tions found in clinical guidelines. Consequently,
preferences of AF patients may be one important and
potentially modifiable explanation for the often observed
OAC undertreatment of patients [50, 51]. Therefore, it is of
utmost importance to not only identify but also to under-
stand patient preferences with regard to anticoagulation
treatment in order to improve adherence to guideline rec-
ommendations. Besides that, it is also important that the
treating physician educates and informs the patient about
stroke and bleeding risks since, in that way, adherence to
guideline recommendations can be further improved. All
the publications we analysed reported a high variability of
AF patient preferences towards anticoagulation treatment;
some of the analyses even identified specific AF patient
segments, defined by different degrees of bleeding risk
aversion.
The above-mentioned results were confirmed by two
previous systematic reviews. The authors of the first review
concluded that higher patient values and preferences
regarding thromboprophylaxis treatment may depend on
patients’ prior experience with the treatments, as well as on
the methods used for preference elicitation [52]. The sec-
ond review argued that AF patient preferences may indi-
cate that fewer patients would take VKAs compared with
the recommendations of the guidelines. Based on this
review, at a stroke rate of 1 % with aspirin, half of the
participants would prefer VKAs and, at a rate of 2 % with
aspirin, two thirds would prefer VKA treatment [53].
As shown in our review, a second part of the scientific
literature analysed the preferences of AF patients towards
OAC treatment by including ‘convenience’ attributes, which
characterise the alternative OAC treatment options, VKAs
and NOACs. Generally, the published data show that AF
patients, in accordance with clinical guidelines, weigh clin-
ical attributes such as stroke or bleeding risk more heavily
than convenience attributes. Therefore, it is in line with the
preferences of AF patients that a treating physician first
investigates the clinical effectiveness and safety of the rec-
ommended anticoagulant before suggesting alternative
treatment choices to the patient. However, this review also
showed that if alternative OAC treatments are similar in
terms of efficacy and safety, as is the case with many anti-
coagulation options in AF, convenience attributes such as
mode of application, interactions with food or drugs, avail-
ability of an antidote, need for bridging, or frequency of
application may matter to patients. Furthermore, patients
may not only have a preference for a more convenient mode
of application but the adherence of patients may also depend
on the convenience of medication therapy. Thus, it has been
shown that a less frequent dosing schedule, such as once
daily on chronic cardiovascular disease medication, is
associated with higher treatment adherence [54].
We also identified a variability of results with regard to
preferences towards these convenience attributes, which
could be explained by several reasons. First, patients
analysed in the included studies were different from each
other in terms of sociodemographic characteristics, study
site characteristics (inpatient versus outpatient treatment,
general practitioners [GPs] versus cardiologists) and cur-
rent anticoagulation treatment, or in terms of the treatment
experience of surveyed patients. For example, one German
study found that AF patients currently treated with VKAs
for at least 3 months (which may be an indicator of
stable anticoagulation) did not show any clear preference
for or against monthly blood checks, whereas patients
treated with an NOAC agent had a clear preference against
such checks [41]. Thus, it is important to inform the patient
about the differences between NOACs and VKAs, which
are apparent in the need for regular blood checks, amongst
others. With VKAs, regular checks are necessary, whereas
with NOACs, no regular checks are needed.
Second, study methodologies differed markedly
between the different studies in terms of the number of
included study sites, patient inclusion criteria and patient
selection, and the preference elicitation technique used.
Because of this, it cannot be ruled out that the selected
questions in the descriptive questionnaires used in several
studies also influenced reported results. In some studies,
interviews were conducted face-to-face, whereas others
used phone, written or online interviews, therefore inter-
viewer bias cannot be excluded in these studies [29]. On
the other hand, when questionnaires were sent out to par-
ticipants, there was the risk of non-response bias, poten-
tially leading to skewed results of the study [25].
Three studies analysing preferences towards NOACs
versus VKAs used trade-off/standard gamble techniques.
These comprise a method that offers the opportunity to
compare therapy preference between two different options
[45]. The hypothetical efficacy of the intervention is sys-
tematically varied until the lowest risk reduction, the point
at which patients are willing to take the therapy, is found
[28]. A disadvantage of this method is that the considera-
tion of more than two options might generate confusion or
fatigue in respondents, resulting in a notable proportion of
respondents indicating initial choices that were internally
inconsistent [55].
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Finally, four studies applied a conjoint analysis/discrete
choice experiment (DCE) to analyse preferences towards
either NOACs or VKAs. DCE was introduced into health
economics as a technique to identify the key characteristics
of alternative treatments because patients were concerned
with aspects of healthcare other than only clinical out-
comes. This method has been used to elicit preferences for
health and healthcare in a range of contexts and is now, to a
certain degree, seen as a gold-standard technique. The
method assumes that the value of medical treatments
depends on a number of characteristics. DCE allows one to
simultaneously weigh various characteristics of different
therapeutic options and to establish the relative importance
of each characteristic in the implementation of that thera-
peutic option. It can also be used to estimate how indi-
viduals trade these characteristics; for instance, the rate at
which they are willing to give up one characteristic for an
increase in another [56]. The main reason for applying a
DCE is that simply asking patients to rate treatment-related
attributes generally yields no substantial information since
patients will state in such a survey that they want all the
benefits and none of the indirect/direct costs [57]. One
advantage of applying a DCE is that patients are forced to
make a trade-off between two or more options and that they
have to choose, as is the case in reality, between options
that may be associated with utility-increasing and utility-
decreasing attribute levels [58].
The studies included in our review that used a DCE
technique came to similar conclusions. An Australian study
that included both clinical and convenience attributes
concluded that the overall profiles of NOACs, compared
with VKA treatment, are preferred by patients, especially if
an antidote exists and if there are reasonable costs for
NOAC treatment [18]. Similarly, in an Italian study that
included bleeding risk as an attribute, patients preferred
once-daily tablet treatment without regular monitoring
[56]. In a German DCE study, AF patients also favoured
attribute levels that are best presented by a once-daily
NOAC treatment [41].
In addition to the above-mentioned difficulties in com-
paring the identified studies, due to differences in their
methodology, we acknowledge two additional limitations.
First, our research was based on a review of publications
available in the selected databanks only and, second, due to
methodological differences between the studies, we did not
conduct a quantitative meta-analysis.
5 Conclusions
Our review of the preferences of AF patients towards
anticoagulation shows that stroke risk reduction and lim-
ited bleeding risk are the most important attributes for an
AF patient when deciding whether they are for or against a
certain treatment. In the stroke risk/bleeding risk trade-off
assessment, physicians may be more sensitive to bleeding
risk than patients. AF patients are willing to accept higher
bleeding risks if a certain threshold in reduced stroke risk
can be reached.
Treating physicians should take patient preferences
into account when deciding on the type of OAC treat-
ment. If different anticoagulation options have similar
clinical characteristics, convenience attributes matter to
patients. In this review, AF patients favour attribute
levels that describe NOAC treatment (e.g. once-daily
intake, no regular blood tests and less drug/food inter-
action). Whether these convenience advantages may also
contribute to improving the percentage of patients in
need of lifelong OACs in order to receive such a treat-
ment is open for future research.
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